Alembic Pharmaceuticals Limited has informed the Exchange about receipt of Establishment Inspection Report (EIR) for its API - I & API - II Facility located at Panelav
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has informed the stock exchange that it has received the Establishment Inspection Report (EIR) from the US FDA for its two Active Pharmaceutical Ingredient (API) manufacturing facilities located at Panelav, Gujarat. An EIR is issued by the US FDA after the completion of a facility inspection and formally closes out the inspection cycle. The receipt of an EIR generally indicates that the inspection process has been concluded without escalation to further enforcement actions such as a Warning Letter or Import Alert, though the classification of the inspection (OAI, VAI, or NAI) would determine the exact regulatory status. The company manufactures APIs that are exported to the US market, making these inspections critical for ongoing business.
This is a routine regulatory update. If the EIR classifies the facility as acceptable (VAI or NAI), it is a positive signal that US exports from these facilities can continue without disruption, which is important for Alembic's US revenue. Shareholders should look for the company's detailed disclosure on the EIR classification to assess any supply or revenue impact.